JP2022546590A5 - - Google Patents

Info

Publication number
JP2022546590A5
JP2022546590A5 JP2022514665A JP2022514665A JP2022546590A5 JP 2022546590 A5 JP2022546590 A5 JP 2022546590A5 JP 2022514665 A JP2022514665 A JP 2022514665A JP 2022514665 A JP2022514665 A JP 2022514665A JP 2022546590 A5 JP2022546590 A5 JP 2022546590A5
Authority
JP
Japan
Prior art keywords
cells
optionally
seq
domain
chimeric polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022514665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546590A (ja
JP7820819B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/049521 external-priority patent/WO2021046432A1/en
Publication of JP2022546590A publication Critical patent/JP2022546590A/ja
Publication of JP2022546590A5 publication Critical patent/JP2022546590A5/ja
Application granted granted Critical
Publication of JP7820819B2 publication Critical patent/JP7820819B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022514665A 2019-09-06 2020-09-04 がんの処置のためのキメラ抗原受容体ならびに関連した方法および組成物 Active JP7820819B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962897062P 2019-09-06 2019-09-06
US62/897,062 2019-09-06
PCT/US2020/049521 WO2021046432A1 (en) 2019-09-06 2020-09-04 Chimeric antigen receptors and related methods and compositions for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2022546590A JP2022546590A (ja) 2022-11-04
JP2022546590A5 true JP2022546590A5 (cg-RX-API-DMAC7.html) 2023-09-11
JP7820819B2 JP7820819B2 (ja) 2026-02-26

Family

ID=74852083

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022514665A Active JP7820819B2 (ja) 2019-09-06 2020-09-04 がんの処置のためのキメラ抗原受容体ならびに関連した方法および組成物

Country Status (8)

Country Link
US (1) US20230049954A1 (cg-RX-API-DMAC7.html)
EP (1) EP4025225A4 (cg-RX-API-DMAC7.html)
JP (1) JP7820819B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220077127A (cg-RX-API-DMAC7.html)
CN (1) CN114765980A (cg-RX-API-DMAC7.html)
CA (1) CA3153311A1 (cg-RX-API-DMAC7.html)
IL (1) IL291090A (cg-RX-API-DMAC7.html)
WO (1) WO2021046432A1 (cg-RX-API-DMAC7.html)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323322B1 (en) * 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
GB0523954D0 (en) * 2005-11-24 2006-01-04 Ucb Celltech Bioassays
WO2009086132A2 (en) * 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
UA99339C2 (ru) * 2008-03-12 2012-08-10 Имклоун Ллк Антитело, которое специфично связывает человеческий tyrp1
EP3202783A1 (en) * 2016-02-02 2017-08-09 Ecole Polytechnique Fédérale de Lausanne (EPFL) Engineered antigen presenting cells and uses thereof
EP3432924A1 (en) * 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
WO2018075586A1 (en) * 2016-10-18 2018-04-26 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof
US10415017B2 (en) * 2017-05-17 2019-09-17 Thunder Biotech, Inc. Transgenic macrophages, chimeric antigen receptors, and associated methods
US11241485B2 (en) * 2017-06-12 2022-02-08 Obsidian Therapeutics, Inc. PDE5 compositions and methods for immunotherapy
CN119193493A (zh) * 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
CA3087476A1 (en) * 2018-01-10 2019-07-18 The General Hospital Corporation Immune cells expressing a chimeric antigen receptor
CA3103610A1 (en) * 2018-06-12 2019-12-19 The Regents Of The University Of California Single-chain bispecific chimeric antigen receptors for the treatment of cancer

Similar Documents

Publication Publication Date Title
IL262321B2 (en) Compositions and methods for selective protein expression
KR20230011959A (ko) 동종이계 이식을 위한 조작된 면역 세포
CA3032054A1 (en) Combination therapies of chimeric antigen receptors and pd-1 inhibitors
EP4194472A1 (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof
CN121779568A (zh) 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
JP2024050549A (ja) 二重特異性t細胞誘導体及びその使用
CA3189677A1 (en) Chimeric molecules providing targeted costimulation for adoptive cell therapy
US20240000938A1 (en) Adoptive cell therapy for treatment of cancer associated with loss of heterozygosity
US20240123068A1 (en) Cd19 binders, car-t constructs comprising the same, and methods of using the same
EP3655440A1 (en) Compositions and methods for targeting cd33-expressing cancers
WO2023160260A1 (zh) Cd7-car-t细胞及其制备方法和应用
JP2023516067A5 (cg-RX-API-DMAC7.html)
US20240226154A9 (en) Car-t constructs comprising a novel cd19 binder combined with il18 and methods of using the same
CN110092836A (zh) 用于治疗胰腺癌或胆管类癌的嵌合抗原受体
EP4041410A2 (en) Engineered trimeric cd70 proteins and uses thereof
WO2023202280A1 (zh) 抗B7H6的scFv抗体、其编码基因及其应用
CA3091143A1 (en) Foxp3 targeting agent compositions and methods of use for adoptive cell therapy
US20240384293A1 (en) Viral vector production system
CN117098782A (zh) 靶向cldn18.2的抗原结合蛋白及其用途
CN115785279A (zh) 包含新型共刺激结构域的嵌合抗原受体及其用途
EP4647445A1 (en) Antigen-binding proteins targeting ror1
US20220370498A1 (en) Immune cells expressing receptor specific to class i mhc molecule and interfering rna for hla gene
US20220315931A1 (en) Immune cells expressing receptor specific to class i mhc molecule and interfering rna for beta2 microglobulin gene
KR20230171919A (ko) Ccr4 표적화 키메라 항원 수용체 세포 요법
WO2026047626A1 (en) Compositions and methods involving immune cells engineered for binding bispecific antibodies for use in cell therapy